10,487 Shares in Biogen Inc. $BIIB Acquired by Aster Capital Management DIFC Ltd

Aster Capital Management DIFC Ltd bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,487 shares of the biotechnology company’s stock, valued at approximately $1,846,000. Biogen accounts for approximately 0.8% of Aster Capital Management DIFC Ltd’s holdings, making the stock its 18th largest holding.

Several other hedge funds have also added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp boosted its position in Biogen by 224.5% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 16,808 shares of the biotechnology company’s stock worth $2,958,000 after buying an additional 11,628 shares during the period. USS Investment Management Ltd boosted its position in Biogen by 7.4% during the 4th quarter. USS Investment Management Ltd now owns 34,216 shares of the biotechnology company’s stock worth $6,022,000 after buying an additional 2,346 shares during the period. MML Investors Services LLC boosted its position in Biogen by 12.9% during the 4th quarter. MML Investors Services LLC now owns 8,225 shares of the biotechnology company’s stock worth $1,448,000 after buying an additional 939 shares during the period. Mariner LLC boosted its position in Biogen by 10.4% during the 4th quarter. Mariner LLC now owns 52,475 shares of the biotechnology company’s stock worth $9,238,000 after buying an additional 4,961 shares during the period. Finally, Nicolet Advisory Services LLC boosted its position in Biogen by 39.7% during the 4th quarter. Nicolet Advisory Services LLC now owns 3,915 shares of the biotechnology company’s stock worth $727,000 after buying an additional 1,112 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Royal Bank Of Canada lifted their target price on shares of Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 27th. JPMorgan Chase & Co. lifted their target price on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. HC Wainwright reiterated a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. Citigroup lifted their target price on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Finally, Argus upgraded shares of Biogen to a “hold” rating in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $216.70.

Biogen Stock Down 0.7%

Shares of NASDAQ BIIB opened at $198.64 on Tuesday. The company has a market capitalization of $29.33 billion, a P/E ratio of 21.31 and a beta of 0.20. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The company’s 50 day moving average price is $189.16 and its 200-day moving average price is $184.48.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts forecast that Biogen Inc. will post 14.18 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.